Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory disease to at least one prior regimen.~* No prior bortezomib therapy.~* Voluntary written informed consent.~* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control.~* Male subject agrees to use an acceptable method for contraception for the duration of the study therapy.~* 18 years of age or older.~* aspartate aminotransferase (AST),alanine aminotransferase (ALT), total bilirubin \< 3 times the upper limit of normal unless documented by the treating physician to be secondary to underlying lymphoma.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~Exclusion Criteria:~* Platelet count of \< 50,000 within 14 days before enrollment unless documented by the treating physician to be due to the disease.~* Absolute neutrophil count of \< 1000 within 14 days before enrollment unless documented by the treating physician to be due to disease.~* Estimated or measured creatinine clearance of less than 30 ml/min within 14 days before enrollment.~* ≥Grade 2 peripheral neuropathy within 14 days before enrollment.~* Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.~* Patient has hypersensitivity to boron, mannitol or any drug included in the current protocol.~* Female subject is pregnant or lactating.~* Received other investigational drugs for this disease within 14 days of enrollment~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~* Known HIV+ status.~* Cardiac ejection fraction less than 35% at study entry measured by echocardiogram, Multigated Acquisition (MUGA) or cardiac MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VR-FND (Type: EXPERIMENTAL): Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.~Each cycle will be repeated every 28 days for 8 cycles maximum.

Based on this trial design, predict the completion outcome and termination type (if applicable).